#USA #Fremont, California #Alamar Biosciences #Gates Ventures #Alzheimer's Disease Data Initiative

Groundbreaking Alliance in Alzheimer’s Research

Alamar Biosciences, a company specializing in precision proteomics aimed at early disease detection, has embarked on a significant partnership with the Alzheimer's Disease Data Initiative and Gates Ventures. This strategic alliance is focused on developing one of the largest proteomic data collections linked to clinical outcomes for Alzheimer's disease (AD).

The collaborative project will analyze over 40,000 plasma samples using Alamar's highly sensitive NULISA™ technology. The mission is clear: to enhance the discovery of biomarkers while gaining insight into the progression and treatment of Alzheimer's disease.

Dr. Yuling Luo, founder, president, and CEO of Alamar Biosciences, expressed the commitment of the partnership stating, "This collaboration represents our joint dedication to transforming Alzheimer’s research through the utilization of data, technology, and global partnerships. By combining our NULISA platform with the infrastructure of the Alzheimer's Disease Data Initiative and the investments of Gates Ventures directed at achieving our mission, we aim to initiate a new era of discoveries and therapies based on biomarkers."

To achieve these goals, Alamar's diagnostics panels, the NULISAseq™ CNS Disease Panel 120 and the Inflammation Panel 250, will be deployed across research centers in the United States, Sweden, the United Kingdom, and India. These panels are noted for their unmatched sensitivity and specificity, allowing for accurate measurements of hundreds of brain-related and immune system proteins from minimal amounts of blood or cerebrospinal fluid.

A notable advancement of the CNS panel is its ability to distinguish between phosphorylated tau originating from the brain and the total phosphorylated tau in the blood. This differentiation marks a significant step in developing effective screening programs within societal efforts. The generated proteomic data will be integrated with clinical study findings and long-term results, subsequently shared with the global scientific community via the secure Global Neurodegeneration Proteomics Consortium (GNPC) data exchange system.

Niranjan Bose, managing director for health and life sciences at Gates Ventures and acting executive director for the Alzheimer's Disease Data Initiative, emphasized the importance of understanding the biological foundations of Alzheimer's disease. “This initiative will provide researchers around the world with a rich resource that will help break long-standing barriers to early detection of the disease and diverse treatment strategies,” he stated.

This venture is a crucial step towards creating a comprehensive, clinically enriched atlas of the plasma proteome for Alzheimer's patients, aiding in the discovery of new biomarkers for diagnosis, prognosis, and treatment efficacy assessment. Additionally, this strategic collaboration is a complement to existing GNPC efforts, where leading dementia scientists and data repositories have united to create one of the largest disease-specific proteomic databases to date.

The project also emphasizes inclusivity, encompassing diverse patient groups across various geographical regions and ethnic backgrounds, which is vital for comprehensive research in Alzheimer's disease.

The Alzheimer's Disease Data Initiative itself is a coalition of leading academic, governmental, industrial, and philanthropic institutions recognizing the need to facilitate the exchange of data, analytical tools, and research outcomes among dementia researchers. Together, they are tackling priority issues that could accelerate progress in developing new diagnostics, treatments, and therapies for Alzheimer's disease and related dementias.

For further information on the Alzheimer’s Disease Data Initiative, please visit www.alzheimersdata.org.

Alamar Biosciences is a private life sciences company dedicated to creating solutions focused on proteomics for early disease detection. Their proprietary NULISA™ platform and ARGO™ HT system are built upon existing knowledge in genomics and provide detection sensitivity at single-digit attomolar concentrations, far exceeding industry standards in protein detection sensitivity. For more information, visit alamarbio.com.